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Progenitor cell–based therapy with the use of autologous bone marrow as a source has been suggested to improve 
left ventricular (LV) function in patients with acute myocardial 
infarction (AMI) if administered after successful percutaneous 
coronary intervention. Indeed, several published studies 
using bone marrow–derived unselected mononuclear cells 
(BM-MNC) showed an improvement in global LV function1–3 
or in regional LV function.4 Others, however, could not confirm 
any beneficial effect of cell therapy on LV function.5,6 Such 
controversial results could be attributable to different study 
designs, different cell isolation protocols potentially leading 
to differences in cell functionality, or the way that end points 
have been assessed. Furthermore, timing of cell administration 
may be an important factor influencing the treatment effect 
of progenitor cell–based therapy. Indeed, in most of the 
studies BM-MNC were administered within the first 7 days 
Background—Intracoronary administration of autologous bone marrow–derived mononuclear cells (BM-MNC) may 
improve remodeling of the left ventricle (LV) after acute myocardial infarction. The optimal time point of administration 
of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials.
Methods and Results—In a multicenter study, we randomized 200 patients with large, successfully reperfused ST-segment 
elevation myocardial infarction in a 1:1:1 pattern into an open-labeled control and 2 BM-MNC treatment groups. In the 
BM-MNC groups, cells were administered either early (ie, 5 to 7 days) or late (ie, 3 to 4 weeks) after acute myocardial 
infarction. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary end point was 
the change from baseline to 4 months in global LV ejection fraction between the 2 treatment groups and the control group. 
The absolute change in LV ejection fraction from baseline to 4 months was −0.4±8.8% (mean±SD; P=0.74 versus baseline) 
in the control group, 1.8±8.4% (P=0.12 versus baseline) in the early group, and 0.8±7.6% (P=0.45 versus baseline) in the 
late group. The treatment effect of BM-MNC as estimated by ANCOVA was 1.25 (95% confidence interval, −1.83 to 4.32; 
P=0.42) for the early therapy group and 0.55 (95% confidence interval, −2.61 to 3.71; P=0.73) for the late therapy group.
Conclusions—Among patients with ST-segment elevation myocardial infarction and LV dysfunction after successful 
reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days or 3 to 4 weeks after acute myocardial infarction 
did not improve LV function at 4-month follow-up.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186.  (Circulation. 
2013;127:1968-1979.)
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after AMI. Interestingly, in a prespecified subgroup analysis 
of the Reinfusion of Enriched Progenitor Cells and Infarct 
Remodeling in Acute Myocardial Infarction (REPAIR-AMI) 
trial, the beneficial effects of BM-MNC appeared to be more 
pronounced with later cell application (ie, 5–7 days).2 The 
Cardiovascular Cell Therapy Network performed 2 trials 
investigating different time points of cell application: The 
recently published Transplantation in Myocardial Infarction 
Evaluation (TIME) trial7 compared BM-MNC therapy at 3 days 
versus 7 days after AMI, whereas the LateTIME trial8 tested 
BM-MNC application 2 to 3 weeks after AMI against placebo. 
In neither one of these trials, however, did BM-MNC therapy 
improve LV function. However, a direct comparison of the 
effects of early versus late BM-MNC application on LV function 
is still lacking. Thus, the Swiss Multicenter Intracoronary Stem 
Cells Study in Acute Myocardial Infarction (SWISS-AMI) 
was designed to prospectively investigate the optimal time of 
BM-MNC administration at 2 different time points: early or 5 
to 7 days versus late or 3 to 4 weeks after AMI.
Editorial see p 1935 
Clinical Perspective on p 1979
Methods
Study Sample and Protocol
The study design with predefined inclusion and exclusion criteria has 
been described previously.9 In brief, patients with acute ST-segment 
elevation myocardial infarction (STEMI) and successful percutane-
ous coronary intervention within 24 hours after symptom onset were 
eligible for enrollment into this multicenter randomized controlled 
trial provided that they presented with an estimated LV ejection frac-
tion (LVEF) of <45% as assessed by an LV angiogram or transtho-
racic echocardiography the day of or after the AMI. After giving their 
informed consent to participate in the study, patients were randomly 
assigned in a 1:1:1 fashion to 1 open labeled control and 2 BM-MNC 
treatment groups. The control group received best medical manage-
ment according to current guidelines,10 including aspirin and clop-
idgrel or prasugrel, statins, β-blockers, and angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers, as well as 
aldosterone antagonists, if indicated. The early BM-MNC treatment 
group received cells at 5 to 7 days and the late BM-MNC group at 3 to 
4 weeks after primary percutaneous coronary intervention, on top of 
best medical management. All patients underwent cardiac magnetic 
resonance imaging (CMR) at baseline and at 4 months after AMI. 
The primary hypothesis was that the change in LVEF at 4 months 
compared with baseline would be more pronounced in both treat-
ment groups compared with control patients. A total of 4 Swiss ter-
tiary centers (University Hospital Zurich, Bern University Hospital, 
Cantonal Hospital Lucerne, and Fondazione Cardiocentro Ticino) 
participated in this trial. The study was conducted in accordance with 
the Declaration of Helsinki, and the protocol was approved by the re-
gional ethical committee of each participating center as well as by the 
federal authorities (Swissmedic and Federal Office of Public Health).
Bone Marrow Aspiration and Cell Processing
Bone marrow aspiration was performed under sterile conditions in 
patients randomly assigned to the BM-MNC treatment arms with 
negative serological testing for hepatitis B, hepatitis C, and HIV either 
5 to 7 days or 3 to 4 weeks after AMI. The cell processing was done 
in a centralized, good manufacturing practice–certified facility (Cell 
Therapy Unit, Cardiocentro Ticino, Lugano, Switzerland). Between 
60 and 80 mL of bone marrow was collected from the iliac crest 
under local anesthesia. Then 1 mL of a solution containing 1000 IU 
heparin was added to each 10 mL of bone marrow aspirate to prevent 
clotting. Then the aspirate and 20 mL of the patient’s serum were 
sent at room temperature by courier to the cell-processing center. The 
BM-MNC cell suspension was shipped back to the participating 
hospital within 24 hours. Shipping protocols as well as the isolation of 
the mononuclear cell fraction were performed according to a standard 
protocol according to previous studies2,11 with minor modifications as 
described.9 Briefly, with the use of density gradient centrifugation, the 
mononuclear cell fraction was resuspended in 10 mL of serum-free 
medium with 20% of autologous serum added without any additional 
heparin. An aliquot of cell suspension was utilized for fluorescence-
activated cell sorting analysis with the use of fluorochrome-
conjugated antibodies against anti-human CD34 and CD133; cell 
viability was assessed by 7-AAD cell uptake, and sterility was 
assessed by the Bact/Alert rapid method. Release criteria of the BM-
MNC were product sterility, a cell count between 5×107 and 5×108, 
and cell viability of ≥80%. Migration capacity of BM-MNC was 
measured in a modified Boyden chamber as described previously.12 
This parameter was expressed as percentage of mononuclear cells 
able to actively cross a membrane coated with extracellular matrix 
proteins and, with the use of an invasion index, indicating the ratio 
between the latter and the percentage of cells passively crossing the 
same membrane when uncoated.
Intracoronary Infusion of BM-MNC
After arterial access was obtained (either via the common femoral 
artery or the radial artery), patients received 5000 IU of heparin 
intravenously. Then an over-the-wire balloon catheter was advanced 
via a guiding catheter in the segment of the former infarct-related 
vessel containing the stent. After inflation of the balloon with 
low pressure (2–4 bar) within the stented segment to obtain total 
occlusion of the vessel, BM-MNC were infused within 3 minutes to 
allow for adhesion and transmigration of the infused cells through 
the endothelium (stop-flow technique). This maneuver was repeated 
3 times to allow for infusion of a total of 9 mL of progenitor cell 
suspension, interrupted by 5 minutes of reflow by deflating the 
balloon to minimize extensive ischemia and pain. Finally, coronary 
angiography was repeated to ascertain vessel patency.
Periprocedural safety of the BM-MNC infusion was monitored by 
assessment of serum cardiac enzymes including cardiac troponin the 
day after the intervention. Periprocedural myocardial infarction was 
defined as described previously.13
Cardiac Magnetic Resonance Imaging
Cardiac imaging was performed with the use of 1.5-T clinical MR 
systems. Dedicated cardiac phased-array receiver coils were used 
for signal reception. Patients underwent CMR studies at baseline 
(ie, during hospitalization for the AMI) and at 4 months of follow-up. 
After localizer acquisitions, the CMR studies assessed functional 
imaging of the LV by means of standard ECG-triggered steady 
state free precession acquisitions during repetitive breath-holds in 
3 long-axis orientations and in contiguous short-axis orientations 
covering the entire LV. In the second part of the CMR examination, 
scar imaging was performed after administration of a bolus of a 
conventional extracellular gadolinium chelates contrast medium 
at a dose of 0.20 mmol/kg body wt by using an inversion-recovery 
fast gradient echo imaging sequence.14,15 After determination of the 
inversion time nulling for normal myocardium, scar imaging was 
performed 20 minutes after administration of contrast medium in 
identical locations as functional data were acquired.
CMR data analysis was performed in a core laboratory (University 
Hospital Zurich) with the use of dedicated cardiac analysis software 
(GTVolume, Gyrotools Ltd, Zurich, Switzerland). LV end-diastolic 
and end-systolic volumes, LVEF, and LV mass were quantified 
for assessment of the primary end point (change of LVEF) and for 
assessment of ventricular remodeling over time in the 3 study groups.
Regional wall motion was assessed by measuring systolic and 
diastolic wall thickness in each of the 6 segments of all acquired slices, 
and thickening of each segment was calculated by subtracting systolic 
and diastolic values. A global thickening index was determined that 
took into account the median of all values of each segment. The same 
index was determined in the infarct territory, taking into account only 
the infarct-related segments.
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The extent of microvascular obstruction, delineated as dark areas 
in the core of the necrotic zone in the late enhancement images, was 
quantified by manually contouring the dark core areas. Scar mass and 
tissue with microvascular obstruction were assessed in grams and 
milliliters (data not shown) and as a percentage of LV mass and of 
scar mass, respectively.
Changes over time (ie, 4 months versus baseline) of volumetric, 
functional, and scar parameters were compared between the groups 
to assess the influence of treatment on global and regional systolic 
function, LV remodeling, and scar mass.
End Points
The primary end point was the absolute change in global LVEF from 
baseline compared with 4-month follow-up between the control 
group and both BM-MNC therapy groups, respectively.
Secondary end points comprised the change in global LVEF from 
baseline to 4 months between control and a combined therapy group, 
as well as changes in LV end-diastolic and end-systolic volume, 
changes in infarct size, changes in the proportion of scar mass to total 
LV mass, and changes in global and regional myocardial thickening. 
To identify predictive markers, we analyzed treatment-marker 
interactions of the primary end point with infarct size, microvascular 
obstruction, baseline N-terminal pro-brain natriuretic peptide, and 
time from onset of chest pain to successful reperfusion therapy of 
the AMI. Prespecified clinical end points were analyzed including 
major adverse events (defined as all-cause death, recurrence of 
myocardial infarction, any coronary revascularization procedure, or 
rehospitalization for heart failure; all at 4 months) and time from 
STEMI to the occurrence of such events at 4 months. Only the first 
event for each patient was included in the analysis.
Statistical Analysis
In general, median and interquartile range (IQR) are presented for 
continuous variables. If criteria for normal distribution were fulfilled, 
variables are presented as mean and SD. Nominal variables are sum-
marized in terms of frequencies and percentages.
For analysis of the primary end point, we performed ANCOVA, 
including LVEF values at 4 months as dependent variables and the 
associated baseline values and the factor treatment as independent 
variables. Estimates of the treatment effect are presented together 
with the 95% confidence interval (CI). Because comparisons of both 
experimental groups with control were considered the primary end 
point, P values were compared with the Bonferroni-corrected signifi-
cance level α=0.025.
The same analysis as for the primary end point was repeated for the 
secondary end points (only ANCOVA analyses are shown). For anal-
yses of the primary and secondary end points, only matched CMR 
data (baseline and 4 months) were used.
As an additional secondary end point, because we sought to find 
easily interpretable predictive markers for treatment success, prespec-
ified continuous baseline markers were split at the median (in 1 case at 
a manually chosen cutoff). With this new variable, the P value for the 
interaction was then computed in an ANCOVA model with LVEF at 4 
months as dependent variable and the associated baseline values, the 
factor treatment, the marker under consideration discretized at cutoff, 
and treatment-marker interaction as independent variables.
To compute regressions for LVEF at 4-month follow-up, further 
ANCOVA analysis involving adjustment for baseline LVEF was per-
formed. A total of 21 binary, 7 nominal, and 40 continuous explana-
tory variables were analyzed separately.
Binary end points were compared between groups with the use of 
the χ2 or Fisher exact test, depending on whether or not expected cell 
frequencies were <5. For continuous outcome independent samples, 
the t or Wilcoxon test was used.
Major adverse cardiac events were defined as the occurrence of 
1 of the predefined clinical scenarios (death, myocardial infarction, 
coronary revascularization, or rehospitalization for heart failure) and 
were compared between groups at 4 months.
For the secondary end points, multiple comparisons were per-
formed, and the analysis of the results shall be designated exploratory. 
Figure 1. Flow diagram of patient 
enrollment until 4-month follow-up. 
BM-MNC indicates bone marrow–derived 
mononuclear cells; CMR, cardiac magnetic 
resonance imaging; PIC, patient informed 
consent; and STEMI, ST-segment elevation 
myocardial infarction. 
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Table 1. Baseline Characteristics of the Included Patients
Control
(n=67)
Early
(n=65)
Late
(n=63) P Value
Age, median (IQR), y 56 (14.5) 55 (15) 62 (15) 0.70*
0.06†
BMI, median (IQR), kg/m2 26.7 (4.4) 27.0 (6.1) 27.0 (4.4) 0.92*
0.89†
Male sex, % 83.6 86.2 82.5 0.18*
1.00†
Hypertension, % 43.3 49.2 38.7 0.60*
0.72†
Hyperlipidemia, % 44.8 40.0 41.9 0.60*
0.86†
Diabetes mellitus, % 17.9 7.7 9.7 0.12*
0.21†
Smoking (active/previous), % 62.7 67.7 40.3 0.60*
0.01†
Family history of CAD, % 35.8 26.1 24.2 0.26*
0.18†
1-/2 -/3-vessel disease, % 64/21/15 54/32/14 57/27/16 0.34*
0.73†
Previous PCI before AMI, % 3.0 3.1 1.6 1.00*
1.00†
Infarct treatment
 Primary PCI, % 94.0 98.5 100.0 0.37*
0.12†
 Concomitant PCI other
than infarct-related artery, %
18.2 12.3 11.1 0.47*
0.32†
 Infarct vessel LAD/LCX/RCA, % 89/3/8 95/2/3 92/3/5 0.51*
0.89†
 Pain to revascularization time, h 4.5 (5) 4.8 (5.4) 4.0 (4.8) 0.57*
0.53†
 Stent diameter, mm 3.5 (0.5) 3.0 (0.5) 3.5 (0.5) 0.73*
0.89†
 Drug-eluting stent, % 71.6 80.0 81.0 0.31*
0.23†
 TIMI flow before PCI 0 (0) 0 (0) 0 (0) 0.31*
0.87†
 TIMI flow after PCI 3 (0) 3 (0) 3 (0) 0.94*
0.81†
 Use of glycoprotein IIb/IIIa inhibitors/bivalirudin, % 71.7 78.5 78.1 0.88*
0.20†
 Maximal creatine kinase, median (IQR), U/L 3671 (3685) 4314 (3561) 3436 (3813) 0.22*
0.78†
 NT-proBNP, median (IQR), ng/L 1103 (1848) 1450 (1442) 1581 (1912) 0.15*
0.10†
 Intra-aortic balloon pump/other assist device, % 16.4 15.6 22.6 1.00*
0.18†
CMR characteristics of LV
 LVEF, median (IQR), % 39.6 (11.2) 34.6 (16.1) 35.6 (11.2) 0.07*
0.03†
 LVEDV, median (IQR), mL 154 (44) 153 (49) 149 (47) 0.89*
0.96†
 LVESV, median (IQR), mL 94 (35) 94 (41) 97 (38) 0.54*
0.41‡
 Scar mass, median (IQR), g 39.1 (37.2) 37.7 (32.1) 33.9 (24.2) 0.94*
0.21†
(Continued)
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P values and 95% CIs are therefore shown without further Bonferroni 
correction. All computations were done with R (R Development Core 
Team, 2012).
Sample Size/Power Calculation
The study has been powered for evaluation of the primary end point 
depending on the presence of paired CMR data, assessed either at 
baseline or at 4-month follow-up.
As described previously9 and according to recent studies,1,2,16 in 
planning sample size we assumed a difference between LVEF im-
provements from baseline to 4 months of δ=3.5% with SD of 6% be-
tween control and both treatment groups. A sample size of n=58 per 
group was therefore needed to detect such difference with a power of 
80% for a Bonferroni-corrected significance level of α=0.025. Taking 
into account a dropout rate of 10%, we planned to include n=64 per 
arm and n=192 for the entire trial. All computations were done with 
R (R Development Core Team, 2012).
Table 1. Continued
Control
(n=67)
Early
(n=65)
Late
(n=63) P Value
 Myocardial scar, median (IQR), % 28.3 (16.3) 28.1 (16.2) 26.6 (15.9) 0.78*
0.53†
 Microvascular obstruction, median (IQR), g 0.27 (1.55) 1.08 (3.00) 0.64 (2.49) 0.11*
0.51†
Medication at discharge/after 4 mo, %
 Aspirin 98.5/98.4 98.4/98.4 98.3/98.2 1.00/1.00*
1.00/1.00†
 Clopidogrel or prasugrel 100/100 100/100 100/98.2 1.00/1.00*
1.00/0.84†
 ACE inhibitor or ATII receptor blocker 95.5/100 100/100 96.6/98.2 1.00/1.00*
1.00/0.84†
 β-Blocker 86.4/85.2 91.9/88.5 93.2/92.6 0.40/0.79*
0.25/0.25†
 Aldosterone antagonist 12.1/11.5 12.9/14.8 15.2/9.3 1.00/0.79*
0.79/0.77†
 Statin 97.0/98.4 100/95.1 98.3/100 0.50/0.62*
1.00/1.00†
ACE indicates angiotensin-converting enzyme; AMI, acute myocardial infarction; ATII, angiotensin II; BMI, body mass index; CAD, coronary artery disease; IQR, 
interquartile range; LAD, left anterior descending coronary artery; LCX, left circumflex artery; LV, left ventricle; LVEDV, LV end-diastolic volume; LVEF, LV ejection 
fraction; LVESV, LV end-systolic volume; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; RCA, right coronary artery; and 
TIMI, Thrombolysis in Myocardial Infarction.
*P value, control vs early group.
†P value, control vs late group.
Table 2. Characteristics of BM-MNC and Cell Treatment
Early
(n=62)
Late
(n=52)
P Value
(Between-Group Difference)
Cell characteristics, median (IQR)
 BM aspiration volume, mL 65 (15) 70 (15) 0.30
 Total nucleated cells, 106 cells 159.7 (125.8) 139.5 (120.5) 0.18
 Viability, % 93.6 (5.55) 93.33 (6.60) 0.98
 % CD34+ cells 1.02 (0.72) 1.31 (0.97) 0.01*
 Total CD34+ cells, 106 cells 1.6 (1.69) 1.45 (2.43) 0.68
 % CD34+/133+ cells 0.81 (0.78) 0.87 (0.97) 0.34
 Total CD34+/133+ cells, 106 cells 0.96 (1.46) 0.92 (2.06) 0.77
 % Invasion 33 (18)† 26.5 (16.5)‡ 0.18
 Invasion index 50.88 (24.38)† 45.64 (22.10)‡ 0.21
Timing of BM-MNC treatment
 Days after AMI 6 (2) 24 (7) NA
AMI indicates acute myocardial infarction; BM, bone marrow; BM-MNC, bone marrow–derived mononuclear cells; IQR, interquartile range; and % invasion, percentage 
of total nucleated cells showing invasion capacity.
*Estimated Wilcoxon effect, −0.31; 95% confidence interval, −0.56 to −0.07.
†n=29.
‡n=30.
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Results
Patient Enrollment and Baseline Characteristics
Between October 2006 and January 2012, in the 4 Swiss cardio-
vascular centers, a total of 200 patients gave informed consent 
to participate in the trial. Of those, 66 patients were randomized 
to the early BM-MNC treatment group and 67 patients each 
to the control and late treatment groups, respectively. Because 
the dropout rate was higher than expected, the initially planned 
sample size had to be increased from 192 to 200 patients, 
thereby allowing us to attain at least 2 study arms with the nec-
essary sample size. Dropouts were more common within the 
late treatment group. Patient flow from randomization until 
4-month follow-up is shown in Figure 1. There was no statisti-
cally significant difference in baseline characteristics between 
the 3 groups apart from a higher age and a lower percentage of 
smokers in the late treatment group as well as a higher baseline 
LVEF in the control group (Table 1). Baseline CMR was per-
formed at a median of 6 (IQR 4) days after the AMI.
Patients who withdrew informed consent or were unwill-
ing to undergo repeat CMR examination; were generally older 
and had higher values of maximal creatine kinase at base-
line, especially in the early treatment group but not in the late 
therapy group. 
Characteristics of Index Myocardial Infarction
Overall, 92% of the patients had anterior STEMI attributable 
to left anterior descending coronary artery occlusion, and the 
median time from onset of chest pain to reperfusion therapy 
was 4.5 hours (IQR, 5.25). Seventy-six percent of the patients 
were treated with glycoprotein IIb/IIIa inhibitors or bivalirudin, 
and 78% received a drug-eluting stent with a median diameter 
of 3.5 mm (IQR, 0.5). The median of maximal creatine kinase 
plasma levels was 3919 U/L (IQR, 3664), and baseline LVEF, 
as assessed by CMR at a median of 6 (IQR, 4) days after the 
index AMI, was 37.4% (IQR, 13.2).
Characteristics of BM-MNC
A total of 153 (119) ×106 nucleated cells were infused. 
Besides an impurity of granulocytes, the mononuclear fraction 
consisted mainly of lymphocytes, monocytes, and a small 
amount of functional hematopoietic, endothelial/angiogenic, 
and mesenchymal precursors (Table I in the online-only Data 
Supplement). Between 1% and 1.3% of the cells were CD34+ 
cells. Complete cell processing data are shown in Table 2. 
There was no significant difference between the early and late 
therapy groups except for a higher percentage of CD34+ cells 
in the late therapy group. For a subset of patients (n=59), we 
performed a functional test; the median (IQR) percentage of 
MNC exhibiting invasion capacity was overall 29% (19), and 
the overall invasion index was 49% (25), without any differ-
ence between early and late BM-MNC treatment groups.
Assessment of LV Function and Remodeling at 
Baseline and 4-Month Follow-Up
Primary End Point
The mean (SD) absolute change in LVEF at 4 months was 
−0.4% (8.8) in the control group, 1.8% (8.4) in the early 
group, and 0.8% (7.6) in the late group (Figure 2). With 
adjustment for baseline LVEF with an ANCOVA model, the 
estimated treatment effect averaged 1.25 (95% CI, −1.83 to 
4.32; P=0.42 versus control) for the early therapy group and 
0.55 (95% CI, −2.61 to 3.71; P=0.73 versus control) for the 
late therapy group (Table 3).
Secondary End Points
When we combined the early and late groups into a common 
BM-MNC therapy group (n=107), the estimated treatment 
effect was 0.85 (95% CI, −1.75 to 3.44; P=0.52 versus control).
Negative remodeling occurred in all 3 groups. The median 
(IQR) LV end-diastolic volume increased from 154 (44) to 175 
(76) mL in the control group, from 153 (49) to 185 (64) mL in 
the early treatment group, and from 149 (47) to 165 (73) mL 
in the late treatment group. Likewise, LV end-systolic volume 
increased from 94 (35) to 114 (68) mL in the control group, 
from 94 (41) to 105 (50) mL in the early treatment group, and 
from 97 (38) to 103 (54) mL in the late treatment group. Only 
for the late treatment group did ANCOVA testing reveal less 
negative remodeling (estimated treatment effect, −14.86; 95% 
CI, −28.98 to −0.74; P=0.04 for LV end-diastolic volume; 
Figure 2. Descriptive statistic (box plot) 
of the mean of the differences between 
left ventricular ejection fraction (LVEF) at 
4 months and LVEF at baseline for control 
vs early and control vs late bone marrow–
derived mononuclear cell treatment.
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Table 3. ANCOVA of Primary and Secondary End Points, as Assessed by Cardiac Magnetic Resonance Imaging, at Baseline and 
4-Month Follow-up
Variable
Group
Difference Between Treatment Groups 
and Control Group*
Control Early Late
Estimate
(95% CI) P Value
Primary end point†
Global LVEF, %
Baseline Median (IQR) 39.6 (11.2) 34.6 (16.1) 35.6 (11.2) 1.25
(−1.83 to 4.32)‡
0.55
(−2.61 to 3.71)§
0.42‡
0.73§Mean (SD) 40.0 (9.9) 36.5 (9.9) 36.3 (8.2)
4 mo Median (IQR) 38.7 (17.3) 40.1 (14.8) 37.8 (11.7)
Mean (SD) 39.6 (12.0) 37.9 (10.3) 37.4 (9.7)
Secondary end points†
LVEDV, mL
Baseline Median (IQR) 154 (44) 153 (49) 149 (47) 0.92
(−11.95 to 13.78)‡
−14.86
(−28.98 to −0.74)§
0.89‡
0.04§Mean (SD) 153 (38) 156 (41) 157 (37)
4 mo Median (IQR) 175 (76) 185 (64) 165 (73)
Mean (SD) 180 (52) 183 (55) 167 (45)
LVESV, mL
Baseline Median (IQR) 94 (35) 94 (41) 97 (38) −2.06
(−13.5 to 9.38)‡
−10.73
(−22.86 to 1.39)§
0.72‡
0.08§Mean (SD) 94 (33) 100 (36) 100 (29)
4 mo Median (IQR) 114 (68) 105 (50) 103 (54)
Mean (SD) 112 (46) 117 (51) 107 (40)
Mass myocardial scar, g
Baseline Median (IQR) 39.1 (37.2) 37.7 (32.1) 33.9 (24.2) −0.43
(−5.17 to 4.31)‡
−2.99
(−7.64 to 1.66)§
0.86‡
0.20§Mean (SD) 45.3 (28.0) 44.0 (22.3) 38.5 (22.5)
4 mo Median (IQR) 27.8 (17.2) 25.3 (19.7) 21.9 (14.4)
Mean (SD) 29.2 (15.7) 28.9 (15.7) 24.3 (11.1)
Myocardial scar, %
Baseline Median (IQR) 28.3 (16.3) 28.1 (16.2) 26.6 (15.9) −1.15
(−4.19 to 1.89)‡
−1.37
(−4.67 to 1.94)§
0.45‡
0.41§Mean (SD) 29.1 (13.1) 28.2 (11.7) 28.1 (11.9)
4 mo Median (IQR) 24.3 (14.5) 22.2 (12.0) 22.9 (11.1)
Mean (SD) 23.9 (10.4) 22.7 (9.4) 22.4 (8.5)
Global wall thickening (average of all segments), mm
Baseline Median (IQR) 8.7 (2.7) 9.3 (3.5) 8.6 (3.1) −0.21
(−0.66 to 0.23)‡
−0.10
(−0.60 to 0.39)§
0.34‡
0.68§Mean (SD) 9.1 (2.3) 9.5 (2.3) 8.7 (2.2
4 mo Median (IQR) 7.1 (1.9) 6.9 (1.4) 6.6 (2.0)
Mean (SD) 7.2 (1.3) 7.1 (1.3) 7.0 (1.5)
Wall thickening in infarct zone (average of all infarcted segments), mm
Baseline Median (IQR) 1.6 (1.2) 1.7 (2.0) 1.7 (1.6) −0.075
(−0.49 to 0.34)‡
0.064
(−0.41 to 0.54)§
0.72‡
0.79§Mean (SD) 1.7 (1.2) 1.6 (1.2) 1.9 (1.2)
4 mo Median (IQR) 2.0 (1.8) 2.1 (1.4) 2.1 (1.8)
Mean (SD) 2.2 (1.5) 2.2 (1.2) 2.2 (1.4)
CI indicates confidence interval; IQR, interquartile range; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; and LVESD, left 
ventricular end-systolic volume. Example for analysis of the primary end point (control group=reference level; intercept = 9.37; LVEF baseline=0.76): For the early 
group, patients have on average a LVEF value at 4 mo that is 9.37+0.76×(the patient’s baseline LVEF) +1.25. For a patient with a mean LVEF of 38%, a LVEF at 4 months 
of 9.37+0.76 ×38+1.25=39.5. CIs and P values are adjusted for baseline LVEF.
*Estimates of regression coefficient of treatment from the ANCOVA models.
†Descriptive statistic [median (IQR) and mean (SD)] of all available parameters at a given time.
‡P value, control vs early group.
§P value, control vs late group.
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−10.73; 95% CI, −22.86 to 1.39; P=0.08 for LV end-systolic 
volume). In all groups, total scar mass uniformly decreased by 
>10 g, corresponding to a 4% to 5% decrease in the proportion 
of myocardial scar with respect to the entire myocardial mass.
Global LV thickening decreased slightly in all 3 groups. 
In contrast, myocardial thickening in the infarct-related seg-
ments showed only negligible changes. For both parameters, 
no treatment-related between-group difference was found. 
The entire results of CMR analyses at baseline and 4 months 
as well as ANCOVA testing are shown in Table 3.
In a prespecified analysis for predictors of BM-MNC treat-
ment effect, the entire patient sample was split according to 
the median value of selected variables. No significant interac-
tion was found for infarct size and for microvascular obstruc-
tion (split at the median). However, an interaction with the 
treatment effect of BM-MNC was found for time from onset 
of chest pain to successful reperfusion therapy (P=0.0455 
for early versus control; P=0.0035 for late versus control) as 
well as for the baseline value of N-terminal prohormone of 
brain natriuretic peptide (P=0.023 for early versus control; 
P=0.0097 for late versus control). Interestingly, early-reper-
fused patients (below the median value of 4.5 hours) demon-
strated an importantly higher treatment effect of BM-MNC 
(Figure 3), injected either early or late after AMI, compared 
with controls (estimated treatment effect of 6.31; 95% CI, 
0.13–12.48; P=0.046 for early BM-MNC therapy group; esti-
mated treatment effect of 9.17; 95% CI, 3.08–15.26; P=0.004 
for late BM-MNC therapy group). Likewise, patients with 
higher N-terminal prohormone of brain natriuretic peptide 
levels at baseline (above the median value of 1437 ng/L) 
demonstrated a higher effect of BM-MNC treatment in both 
therapy groups compared with controls (estimated treat-
ment effect of 7.1; 95% CI, 1.00–13.20; P=0.023 for early 
BM-MNC therapy group; estimated treatment effect of of 
9.02; 95% CI, 2.24–15.79; P=0.01 for late BM-MNC therapy 
group). In regard to the absence or presence of microvascular 
obstruction at baseline, results were inconsistent, showing sig-
nificant interaction for the late but not the early therapy group.
Overall, regression analysis (Table II in the online-only 
Data Supplement) did not show an influence of cell-related 
parameters (total number of mononuclear cells, total number 
of CD34+ and CD133+ cells, proportion of CD34+ and CD133+ 
cells, and migratory capacity) or age on LVEF at 4 months, 
adjusted for baseline LVEF.
Clinical Follow-Up and Events
At 4 months, >75% of the patients were in New York Heart 
Association class I, and >92% were in Canadian Cardiovas-
cular Society class I. There was no difference between groups 
(Table III in the online-only Data Supplement). The clinical 
event rates are shown in Table 4. Events occurring between 
randomization and cell therapy and the cumulative 4-month 
rates are presented separately. Overall mortality at 4 months 
was low (2%) despite the fact that high-risk patients with 
large AMIs were enrolled. No deaths were noted in the con-
trol group, whereas 1 patient (1.7%) died in the late treatment 
group and 3 (4.6%) in the early treatment group. Of note, 
however, 2 deaths (1 in each group) occurred between ran-
domization and a scheduled BM-MNC treatment. There was 
no significant difference in the frequency of isolated serious 
adverse events at 4 months between the 3 groups or for the 
prespecified, combined clinical end point of death, recurrence 
Figure 3. Descriptive statistic (box plot) of the mean of the differences between left ventricular ejection fraction at 4 months and left 
ventricular ejection fraction at baseline depending on time from onset of pain to reperfusion therapy (control vs early bone marrow–
derived mononuclear cell group (left) and for control vs late bone marrow–derived mononuclear cell group (right).
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of myocardial infarction, repeated coronary revascularization, 
or rehospitalization for heart failure.
Discussion
The SWISS-AMI trial, to the best of our knowledge, is the first 
randomized controlled clinical study that addresses both an 
early and a late time point of BM-MNC administration after 
AMI. Both therapy groups were compared with a control arm 
in a unique trial design, assuming an equal treatment effect. 
The study design and power calculation were based on the 
knowledge and data available in 2006 for the calculation of 
adequate sample size. Furthermore, standardized state-of-the-
art cell processing and the best imaging modality (ie, CMR) 
were used to test this hypothesis. Surprisingly, the results of 
our study do not confirm any significant improvement of global 
LV function at 4-month follow-up, either with early (5–7 days) 
or with late (3–4 weeks) application of BM-MNC after a first 
and rather large AMI. Accordingly, the between-group mean 
difference between early cell therapy and control was 2.1% 
(SD >8%), which is far from the 3.5% improvement (SD 6%) 
that was assumed for sample size calculation. For none of the 
secondary end points could a consistent benefit of cell therapy 
for both the early and late therapy groups be found.
Among the 5 potential predictors for a significant treatment 
effect analyzed, we identified N-terminal prohormone of brain 
natriuretic peptide levels above the median and time from 
onset of chest pain to reperfusion therapy below the median of 
4.5 hours as the most promising. A potential explanation for 
the latter finding may be that early reperfusion after AMI leads 
to lower infarct transmurality but not to a lower infarct size or 
to less microvascular obstruction, as shown previously.17 In 
agreement with the results of a smaller trial,18 we suggest that 
in patients with complete transmural scar, BM-MNC treat-
ment may be less beneficial. Further analyses of the 12-month 
CMR data, currently under way, will reveal whether remodel-
ing is favorably affected by BM-MNC therapy in the long run.
Our study fulfilled several prerequisites for a properly 
designed randomized clinical trial testing progenitor cell–
based therapy. First, we managed to enroll mainly patients 
with a large myocardial infarction, as demonstrated by an 
overall median LVEF of 37% and a rather high peak plasma 
level of creatine kinase. This was not the case in most of the 
previous trials.1–3 The size of AMI has been shown to favor 
the beneficial effects of cell therapy in subgroup analyses.2,19 
Thus, the patient population of the SWISS-AMI trial was 
uniquely suited to show a potential benefit of cell therapy. 
Second, the assessment of cardiac function and infarct param-
eters was based on CMR, which is currently considered the 
gold standard for the analysis of global and regional LV func-
tion20,21 and is recognized as one of the most accurate tech-
niques to quantify necrotic or fibrous tissue.22–24 Moreover, 
the entire analysis was performed in a CMR core laboratory, 
blinded to the treatment assignment of the patients enrolled. 
In agreement with previous studies that used CMR to assess 
LV function, the changes in LVEF and remodeling were over-
all small or negligible.4–6,8,19,25 Furthermore, for interpreta-
tion of the data, the time point of the baseline CMR study 
may be important. To account for the early improvement in 
LV function because of recovery of stunned myocardium, we 
performed the baseline examination at day 6 after AMI. This 
could explain the absence of improvement of LVEF in the 
control group from baseline to the 4-month follow-up, which 
was notable, for instance, in the REPAIR-AMI study.2
Third, the processing of BM-MNC was performed by 
an experienced26 and certified core laboratory, with a stan-
dardized protocol used in previous trials.2 Cell potency was 
assessed in vitro as described,12 confirming appropriate 
BM-MNC viability. Furthermore, in vivo experiments using 
the mouse model of myocardial infarction recently described 
by us are currently ongoing.27 Heparin, which potentially 
may abrogate the migration capacity of BM-MNC,28 was not 
added directly to the cells. Like many of the research groups 
working in the field, we chose unselected MNC as treatment 
agents because they have been proven to be safe in previous 
clinical studies and are easy to obtain without complex puri-
fication and cultivation steps. Furthermore, selected MNC of 
any type have never been shown to be superior to unselected 
MNC in terms of neoangiogenesis if confronted directly in 
clinical trials. However, recent studies using selected, bone 
marrow–derived mesenchymal stem cells showed a promis-
ing increase in LVEF shortly after STEMI compared with 
placebo.29 In addition, CD34+ cells have been shown to suc-
cessfully reduce refractory angina if injected directly into the 
ischemic myocardium.30
BM-MNC generally contain a small amount of progenitor 
cells including hematopoietic stem cells, mesenchymal stem 
cells,31 endothelial progenitor cells,32 multipotent adult mesen-
chymal progenitors,33 and very small numbers of embryonic-like 
Table 4. Clinical Events During Follow-up
Control Early Late P Value
Events between randomization
and therapy
 Death
0
1
(3.1)
1
(1.7)
0.24*
0.48†
Events at 4-mo follow-up
(cumulative)
 Death
0
3
(4.8)
1
(1.7)
0.24*
0.48†
 Myocardial infarction 1
(1.6)
1
(1.6)
0
1.00*
1.00†
 Rehospitalization for heart 
failure
2
(3.2)
0
2
(3.6)
0.50*
1.00†
 Revascularization 3
(4.8)
3
(4.9)
2
(3.6)
1.00*
1.00†
Cerebral infarction 1
(1.6)
1
(1.7)
0
1.00*
1.00†
Combined events
 Death, myocardial 
infarction, revascularization, 
rehospitalization for heart failure
4
(6.4)
5
(7.9)
5
(8.8)
1.00*
0.74†
 Death, myocardial 
infarction, revascularization, 
rehospitalization for heart failure, 
stroke
4
(6.4)
6
(9.5)
5
(8.8)
0.74*
0.74†
Values in parentheses are percentages.
*P value, control vs early group.
†P value, control vs late group.
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stem cells.34 Although which subsets of such progenitor cells 
may be responsible for the beneficial effects of BM-MNC in 
AMI has never been clarified, their mechanism of action is 
likely to involve paracrine effects mediated by cells contained 
in unselected BM-MNC, supporting the use of unselected rather 
than selected BM-MNC. Of note, in the SWISS-AMI trial, the 
proportion of CD34+ cells, which are thought to be particularly 
important for neoangiogenesis,35 was 1% in the early and 1.3% 
in the late therapy group; thus, these results were comparable 
to results of previous trials. The total number of injected nucle-
ated cells (overall median of 153 million cells) was lower than 
in the REPAIR-AMI or Bone Marrow Transfer to Enhance 
ST-Elevation Infarct Regeneration (BOOST)1,2 trials but similar 
to the LateTIME trial8 and the TIME trial.7 According to pub-
lished data,36 doses of >150 million of injected mononuclear 
cells (as was used in the SWISS-AMI trial) have been shown 
to be sufficient to modify LV function. In addition, a clear rela-
tionship between total number of injected mononuclear cells or 
CD34+ cells and clinical efficacy has until now not been proven 
in prospective studies.
There are also several limitations of the study. The long dura-
tion between enrollment of the first and the last patients may 
lead to imbalances in the management of STEMI because dur-
ing the study period new antiplatelet agents were introduced 
(such as bivalirudin and prasugrel). In addition, the dropout 
rate differed importantly between groups. Interestingly, the 
dropout rate was the lowest in the early treatment group, in 
which the patients received BM-MNC treatment during the 
initial hospitalization for AMI, whereas in the late treatment 
group it was much higher than expected. This may have led 
to a certain selection bias. Furthermore, baseline LVEF was 
somewhat higher in the control group than in both treatment 
groups. However, when the results of the subgroup analysis 
of 2 previous studies2,19 are considered, this may have dis-
advantaged the results of the control group and thus cannot 
account for the overall disappointing results. Furthermore, in 
the analysis of the primary end point, the results were adjusted 
for baseline LVEF.
Besides the primary end point analysis, we performed a 
large number of statistical tests involving the secondary end 
points, which may increase the overall probability of a type I 
error. The results of the subgroup analysis must therefore be 
considered to be strictly hypothesis generating. Finally, when 
one considers the promising results of recent studies using 
selected cells29,30 such as CD34+ cells or mesenchymal stem 
cells, the lack of cell selection in our study may also be seen 
as an important limitation.
The results of the SWISS-AMI trial may further reduce the 
euphoria that initially accompanied the clinical application 
of progenitor cell–based research. In the last decade, intra-
coronary injection of BM-MNC has been tested in several 
randomized controlled clinical trials, and improvement in 
global LV function has been reported by some1–3 but not all 
of the investigators.4–8,19 The results of the REPAIR-AMI trial2 
in particular were considerably promising and encouraging. 
Potential factors that may have influenced these controversial 
results in terms of LV remodeling may relate to cell function-
ality,37 which has been shown to be abrogated by heparin28 and 
which may be impaired in cardiovascular patients27; selection 
of patients, in particular differences in baseline LVEF and 
infarct size2,19; and choice of the optimal time point of cell 
application. For the latter, initial recommendations were based 
on the work of an expert committee38 in the absence of any 
prospective data.
Simultaneously with the SWISS-AMI trial, the 
Cardiovascular Cell Therapy Network started 2 similar cell 
therapy trials to prospectively address different time points 
of cell administration.7,8 Surprisingly, none of these trials 
could confirm the relevant efficacy of BM-MNC to improve 
LV function at any of the tested time points. BM-MNC 
injection at 2 to 3 weeks after AMI failed to demonstrate 
improvement in LV function in the LateTIME trial compared 
with placebo.8 Although an early treatment group was missing 
in the LateTIME trial, their results are in agreement with 
the results of the late therapy group of SWISS-AMI. In the 
latter trial, injection at 5 to 7 days after AMI showed a small, 
nonsignificant improvement in LVEF, comparable to the 
results of the respective subgroup of the TIME trial.7 When all 
of the randomized clinical trials are considered, with the use 
of CMR to assess global and regional LV function, the effect 
of BM-MNC on LVEF seems to be rather marginal, as shown 
in a meta-analysis.36
In conclusion, in the SWISS-AMI trial in patients with 
STEMI and LV dysfunction after successful reperfusion 
therapy by primary percutaneous coronary intervention and 
intracoronary infusion of BM-MNC either 5 to 7 days or 3 to 
4 weeks after AMI, we did not find improved LV function at 4 
months. The question of whether the measurement of LVEF is 
the proper end point to assess the clinical utility of cell-based 
therapy remains open25 and will await the results of upcoming 
large outcome trials.
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CLINICAL PERSPECTIVE
Bone marrow–derived mononuclear cell (BM-MNC) treatment after acute myocardial infarction is appealing to patients and 
physicians because it represents a drug-free 1-time treatment to improve left ventricular (LV) remodeling. Harvest of bone 
marrow is relatively easy, and intracoronary injection of the BM-MNC has been demonstrated to be feasible and safe shortly 
after myocardial infarction. Many of the randomized controlled trials in the first years after the appearance of BM-MNC 
treatment showed a promising improvement in LV ejection fraction. In the last few years, enthusiasm is decreasing because 
many studies, using mainly cardiac magnetic resonance imaging to assess LV function, did not confirm those results, show-
ing only marginal benefit in favor of BM-MNC treatment. As in 2 other recently published trials of similar study design, in 
the present series there was no significant benefit in favor of BM-MNC in terms of LV remodeling or global or regional LV 
function. Nevertheless, meta-analyses show a potential benefit in terms of prognosis. Whether BM-MNC are the right cell 
type to be used shortly after myocardial infarction cannot be answered by the present study, nor can the question of whether 
LV ejection fraction is the most appropriate surrogate end point. Finally, only the recently begun event-driven phase III 
studies will provide a definitive answer.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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SUPPLEMENTAL MATERIAL
Table S1: BM-MNC characterization II 
 Median (IQR) n 
Lymphocytes (% of total nucleated cells)§ 46 (17) 116 
Monocytes (% of total nucleated cells)§ 8 (3) 105 
CFC (colonies/106 cells)* 4050 (2638) 19 
CFU-Hill (colonies/106 cells)** 11 (11) 6 
CFU-F (colonies/106 cells)*** 12 (11) 15 
IQR: interquartile range; §differential cell counting by automated hematology cell analyzer; *CFC assay for 
the evaluation of hemopoietic cell precursors; **CFU-Hill assay for the evaluation of angiogenic potential; 
***CFU-F for the evaluation of mesenchymal precursors. 
 
Methods (not described in the main article):  
Lymphocytes, Monocytes and Granulocytes were determined by Differential cell count using automated 
hematology cell analyzer (ABX Micros 60, Horiba medical). 
Colony-Forming Cell (CFC) assay was performed plating cells in Methocult® (StemCell Technologies); after 
14 days, plates were microscopically scored for the presence of hematopoietic colonies. For Colony-Forming 
Unit-Hill (CFU-Hill) assay, cells were suspended in Complete CFU-Hill medium (StemCell Technologies), 
then seeded in fibronectin coated 6 well plates; after 2 days, non adherent cell were collected, transferred in 
fibronectin coated 24 well plates and incubated for further 5 days; the wells were then fixed, stained and 
scored for the presence of colonies. For the Colony-Forming Unit-Fibroblast (CFU-F) assay, cells were 
plated in Mesencult®-XF (StemCell Technologies); after 14 days, the dishes were fixed, stained and scored 
for the presence of colonies. 
	  Table S2: Analyses of covariance (ANCOVA) for LVEF, adjusted for 
baseline LVEF and for BM-MNC related variables  
Variable Median (IQR) n Estimate 95% CI p 
Bone marrow aspirate (ml) 70 (15) 105 0.03 -0.08 to 0.13 0.63 
MNC (106 cells) 153 (119) 105 -0.003 -0.02 to 0.01 0.71 
Cell Viability (%) 93.5 (6) 105 -0.04 -0.31 to 0.23 0.79 
% CD34+ cells 1.12 (0.83) 105 -0.94 -2.63 to 0.76 0.27 
Total CD34+ cells (106 cells) 1.55 (1.93) 105 -0.28 -0.91 to 0.35 0.37 
% CD34+/CD133+ cells 0.84 (0.87) 105 0.02 -0.03 to 0.67 0.47 
CD34+/CD133+ cells (106 cells) 0.94 (1.67) 105 -0.07 -0.80 to 0.65 0.84 
% Invasion 29 (19) 55 0.08 -0.08 to 0.23 0.32 
Invasion index 49.3 (25.5) 55 0.05 -0.07 to 0.16 0.42 
Explanation: For each additional ml of bone marrow aspirate and adjusted for baseline LVEF, LVEF at 4 
months is on average changed by 0.03% with 95% confidence interval [-0.08 to 0.13] and p-value 0.63, 
based on 105 complete observations. 
% Invasion: percentage of total nucleated cells showing invasion capacity; MNC: Total nucleated cells 
	  
	  
Table S3: NYHA and CCS Class at 4 months follow-up 
NYHA class Control Early Late p 
  1 52 (85.2%) 46 (75.4%) 43 (76.8%) 
  2 6 (9.8%) 13 (21.3%) 12 (21.4%) 
  3 2 (3.3%) 2 (3.3%) 1 (1.8%) 
  4 1 (1.6%) 0 0 
0.23 * 
0.24 ‡ 
CCS class Control Early Late p 
  1 59 (96.7%) 56 (91.8%) 53 (94.6%) 
  2 1 (1.6%) 3 (4.9%) 3 (5.4%) 
  3 1 (1.6%) 2 (3.3%) 0 
  4 0 0 0 
0.51 * 
0.35 ‡ 
NYHA: New York Heart association;  CCS: Canadian Cardiac society 
*: p value control vs. early;  ‡: p value control vs. late 
	  
